3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Classical hematology
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Waldenstrom Macroglobulinemia
1
Thrombocytopenia
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Hodgkin Disease
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
eltrombopag
14
romiplostim
7
avatrombopag
6
Cytarabine
6
Platelet Transfusion
5
Filgrastim
4
Etoposide
4
Carboplatin
4
oprelvekin
3
Tranexamic Acid
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Daunorubicin
3
Cyclophosphamide
3
Busulfan
3
hetrombopag
2
fludarabine phosphate
2
Tretinoin
2
Thrombopoietin
2
Lenalidomide
2
Interleukin-11
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Doxorubicin
2
Cyclosporine
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
sodium thiosulfate
1
siltuximab
1
sargramostim
1
raltitrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thrombocytopenia
×
Pharmacokinetics
×
Clear all
NCT04861181
2025-05-22
NIRAPK
Hospices Civils de Lyon
Phase 4
Terminated
12 enrolled